Trial Profile
Longterm Follow-up of Subjects Treated With bb2121
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Idecabtagene vicleucel (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors bluebird bio; Celgene Corporation
- 20 Jan 2020 Status changed from recruiting to completed.
- 30 Aug 2018 Planned End Date changed from 1 Apr 2035 to 28 Apr 2035.
- 30 Aug 2018 Planned primary completion date changed from 1 Apr 2035 to 28 Apr 2035.